The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Jennifer G. Robinson | John J. Connolly | J. Gallacher | Toshiko Tanaka | M. Nalls | A. Singleton | J. Manson | A. Reiner | L. Ferrucci | D. Lawlor | H. Hakonarson | J. Boer | N. Timpson | E. Benjamin | R. Schnabel | Yiran Guo | J. Hardy | S. Humphries | A. Hingorani | P. Talmud | S. Redline | P. Whincup | J. Peto | M. Marmot | R. Houlston | J. Whittaker | R. Topor-Madry | N. Wareham | A. Hamsten | U. de Faire | J. Jukema | S. Bielinski | J. Robinson | R. Westendorp | I. Tomlinson | F. Dudbridge | G. Lowe | James G. Wilson | Philip N. Howard | G. Smith | J. Luan | C. Eaton | N. Forouhi | C. Langenberg | P. van der Harst | Y. Ben-Shlomo | B. Sennblad | J. Price | D. Baldassarre | E. Tremoli | A. Wong | M. Burnett | S. Epstein | M. Kumari | M. Kivimaki | D. Kuh | G. Navis | I. Tzoulaki | E. Brunner | F. Fowkes | M. Bobák | J. Casas | R. Hardy | R. Kubínová | S. Malyutina | A. Pająk | H. Pikhart | A. Tamosiunas | P. D. de Jong | S. Bakker | I. Ford | R. Gansevoort | F. Asselbergs | F. Drenos | L. Lange | M. Holmes | R. Morris | Y. T. van der Schouw | N. Onland-Moret | Y. van der Graaf | I. Mateo Leach | A. de Boer | J. Cooper | M. Dunlop | B. Keating | O. Klungel | J. Connolly | K. Kuchenbaecker | M. Voevoda | R. Sofat | N. Sattar | M. Leusink | R. Pfister | Marlene C. W. Stewart | J. Palmen | J. Hubacek | J. Meschia | C. Wassel | J. Stephens | S. Mooijaart | P. Doevendans | J. Devaney | W. Verschuren | A. Peasey | T. Shah | Kawah Li | J. Engmann | D. Swerdlow | C. Chung | H. Ireland | Y. Li | M. Baceviciene | Stefania Bandenelli | Gert Jan de Borst | A. Mailand-van der Zee | T. Frayling | J. Delaney | B. A. Castillo | P. van der harst | A. Tamošiūnas | Toshiko Tanaka | J. Cooper | Irene Mateo Leach | J. Price | J. Hardy | Timonthy M Frayling

[1]  J. Kremer,et al.  Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results , 2013, The Journal of Rheumatology.

[2]  S. Humphries,et al.  Association between the rs1050450 glutathione peroxidase-1 (C > T) gene variant and peripheral neuropathy in two independent samples of subjects with diabetes mellitus. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  Bruce M Psaty,et al.  Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. , 2011, Atherosclerosis.

[4]  Michael Jones,et al.  Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. , 2011, Journal of the National Cancer Institute.

[5]  Ricardo Blanco,et al.  Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. , 2011, Arthritis and rheumatism.

[6]  J. Danesh,et al.  Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data , 2011, BMJ : British Medical Journal.

[7]  V. Salomaa,et al.  C-reactive protein-associated genetic variants and cancer risk: findings from FINRISK 1992, FINRISK 1997 and Health 2000 studies. , 2011, European journal of cancer.

[8]  T. Assimes,et al.  Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies , 2011, The Lancet.

[9]  M. Leinonen,et al.  Association of IL-6 and IL-6R gene polymorphisms with susceptibility to respiratory tract infections in young Finnish men. , 2011, Human immunology.

[10]  Anbupalam Thalamuthu,et al.  A combined analysis of genome-wide association studies in breast cancer , 2011, Breast Cancer Research and Treatment.

[11]  A. Ogata,et al.  Tocilizumab for the treatment of rheumatoid arthritis , 2010, Expert review of clinical immunology.

[12]  D. Grobbee,et al.  Cohort profile: the EPIC-NL study. , 2010, International journal of epidemiology.

[13]  A. Morris,et al.  Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2 , 2010, Nature Genetics.

[14]  Marcia M. Nizzari,et al.  Candidate Gene Association Resource (CARe): Design, Methods, and Proof of Concept , 2010, Circulation. Cardiovascular genetics.

[15]  N. Nishimoto,et al.  Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions , 2010, Modern rheumatology.

[16]  P. Sandercock,et al.  Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.

[17]  S. Humphries,et al.  Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. , 2010, European heart journal.

[18]  J. Scheller,et al.  ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. , 2010, Biochimica et biophysica acta.

[19]  Meena Kumari,et al.  Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms , 2010, Circulation.

[20]  C. Khor,et al.  Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease , 2010, Nature Genetics.

[21]  S. Yamasaki,et al.  Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis , 2011, Rheumatology International.

[22]  Amy Ka Man Yung,et al.  ▼Tocilizumab for rheumatoid arthritis , 2009, Drug and Therapeutics Bulletin.

[23]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[24]  Shahrul Mt-Isa,et al.  Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[25]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[26]  P. Macfarlane,et al.  Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events? , 2009, PLoS medicine.

[27]  M. Urowitz,et al.  Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. , 2009, Seminars in arthritis and rheumatism.

[28]  N. Sattar,et al.  Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions , 2009, Annals of the rheumatic diseases.

[29]  C. Gieger,et al.  Joint analysis of individual participants’ data from 17 studies on the association of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index , 2009, Annals of medicine.

[30]  M. Jokela,et al.  The Whitehall II Study , 2009 .

[31]  B. Thiers.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2009 .

[32]  G. Plosker,et al.  Tocilizumab: a review of its use in the management of rheumatoid arthritis. , 2009, Drugs.

[33]  J. Chang-Claude,et al.  A pilot genome-wide association study of early-onset breast cancer , 2009, Breast Cancer Research and Treatment.

[34]  Rebecca M Reynolds,et al.  The Edinburgh Type 2 Diabetes Study: study protocol , 2008, BMC endocrine disorders.

[35]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[36]  Mark I. McCarthy,et al.  Concept, Design and Implementation of a Cardiovascular Gene-Centric 50 K SNP Array for Large-Scale Genomic Association Studies , 2008, PloS one.

[37]  M. Genovese,et al.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.

[38]  A. Coombs,et al.  Actemra poised to launch IL-6 inhibitors , 2008, Nature Biotechnology.

[39]  Meena Kumari,et al.  Does High C-reactive Protein Concentration Increase Atherosclerosis? The Whitehall II Study , 2008, PloS one.

[40]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[41]  Philippe Froguel,et al.  Common genetic variation near MC4R is associated with waist circumference and insulin resistance , 2008, Nature Genetics.

[42]  Mark I. McCarthy,et al.  A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs) , 2008, PLoS genetics.

[43]  Ludwig A Hothorn,et al.  Repeated Replication and a Prospective Meta-Analysis of the Association Between Chromosome 9 p 21 . 3 and Coronary Artery Disease , 2008 .

[44]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[45]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[46]  D. Melzer,et al.  Middle-aged and mobility-limited prevalence of disability and symptom attributions in a national survey , 2006, Journal of General Internal Medicine.

[47]  B. Team.  British Women's Heart and Health Study: Data and study instruments , 2008 .

[48]  S. Bandinelli,et al.  A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects , 2007, Genes and Immunity.

[49]  C. Gieger,et al.  Genomewide association analysis of coronary artery disease. , 2007, The New England journal of medicine.

[50]  Oliver Sieber,et al.  A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 , 2007, Nature Genetics.

[51]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[52]  T. Hudson,et al.  Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. , 2007, American journal of human genetics.

[53]  Debbie A Lawlor,et al.  Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[54]  M. Marmot,et al.  BMC Public Health BioMed Central Study protocol , 2006 .

[55]  P. Emery,et al.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.

[56]  Juan P Casas,et al.  Insight into the nature of the CRP-coronary event association using Mendelian randomization. , 2006, International journal of epidemiology.

[57]  Sarah Parish,et al.  Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. , 2006, International journal of epidemiology.

[58]  Lon Cardon,et al.  Lymphotoxin-α Gene and Risk of Myocardial Infarction in 6,928 Cases and 2,712 Controls in the ISIS Case-Control Study , 2006, PLoS genetics.

[59]  R. Collins,et al.  Genome-Wide Mapping of Susceptibility to Coronary Artery Disease Identifies a Novel Replicated Locus on Chromosome 17 , 2006, PLoS genetics.

[60]  C. Power,et al.  Cohort profile: 1958 British birth cohort (National Child Development Study). , 2006, International journal of epidemiology.

[61]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[62]  Y. Ohsugi,et al.  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. , 2005, International immunopharmacology.

[63]  A. Ashworth,et al.  Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study , 2005, The Lancet.

[64]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[65]  I. McInnes,et al.  Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions , 2005, Current opinion in rheumatology.

[66]  Michael Marmot,et al.  Cohort Profile: the Whitehall II study. , 2005, International journal of epidemiology.

[67]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[68]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[69]  P. Whincup,et al.  The British Regional Heart Study 1975-2004. , 2004, International journal of epidemiology.

[70]  M. Margaglione,et al.  Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of β-fibrinogen genotype and environmental factors , 2004, Thrombosis and Haemostasis.

[71]  K. Akazawa,et al.  Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced , 2004, Genes and Immunity.

[72]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[73]  R. Handa.  Management of rheumatoid arthritis. , 2004, The National medical journal of India.

[74]  S. Humphries,et al.  Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. , 2004, European heart journal.

[75]  A. Algra,et al.  Second Manifestations of ARTerial disease (SMART) study: Rationale and design , 1999, European Journal of Epidemiology.

[76]  Scott Davis,et al.  Implementation of the Women's Health Initiative study design. , 2003, Annals of epidemiology.

[77]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[78]  Scott Silliman,et al.  The Ischemic Stroke Genetics Study (ISGS) Protocol , 2003, BMC neurology.

[79]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[80]  D. Lawlor,et al.  Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study , 2003, Journal of epidemiology and community health.

[81]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[82]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[83]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[84]  S. Redline,et al.  Genetics of the apnea hypopnea index in Caucasians and African Americans: I. Segregation analysis , 2002, Genetic epidemiology.

[85]  John Hardy,et al.  The Siblings With Ischemic Stroke Study (SWISS) Protocol , 2002, BMC Medical Genetics.

[86]  Simon A. Jones,et al.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  Luigi Ferrucci,et al.  Subsystems Contributing to the Decline in Ability to Walk: Bridging the Gap Between Epidemiology and Geriatric Practice in the InCHIANTI Study , 2000, Journal of the American Geriatrics Society.

[88]  H. Crijns,et al.  Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND I , 2000, The American journal of cardiology.

[89]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[90]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[91]  N. Day,et al.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.

[92]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[93]  G Dunn,et al.  Rationale and design. PRiSM Psychosis Study I. , 1998, The British journal of psychiatry : the journal of mental science.

[94]  T. Meade,et al.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.

[95]  E. Wolf,et al.  The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL- 6 and prolongation of the plasma half-life of IL-6 , 1996, The Journal of experimental medicine.

[96]  S. Redline,et al.  The familial aggregation of obstructive sleep apnea , 1995 .

[97]  C. Palmer,et al.  Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes Project , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[98]  J. Cooper,et al.  The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.

[99]  P. Heinrich,et al.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. , 1994, Journal of immunology.

[100]  P. Heinrich,et al.  The soluble interleukin‐6 receptor is generated by shedding , 1993, European journal of immunology.

[101]  Mindy Seering,et al.  Study protocol. , 1992, Occasional paper.

[102]  R. Prescott,et al.  Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. , 1991, International journal of epidemiology.

[103]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[104]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[105]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.

[106]  A. Fehily,et al.  Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group. , 1984, Journal of epidemiology and community health.

[107]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[108]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[109]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.